Pfizer (PFE) has been dismissed as a defendant in the sweeping multi-state generic drug price-fixing antitrust lawsuit, removing a material legal liability that had shadowed the company’s long-term earnings profile.
For investors focused on pipeline durability and margin trajectory, the dismissal...